Lauren Kaskiel brings over 20 years of experience in the biotech and pharmaceutical industry, with a strong track record in corporate strategy, business development, and alliance management across gene therapy and genetic medicines. She is currently Chief Business Officer at AAVantgarde Bio.

Prior to joining AAVantgarde, Lauren served as Chief Business Officer at Code Biotherapeutics, where she led corporate and business development, alliance management, investor relations, and intellectual property. She was instrumental in securing strategic licenses and collaborations, and driving pipeline expansion through both internal innovation and external partnerships.

Earlier, Lauren held senior roles at Spark Therapeutics, including Chief of Staff to the CEO and Corporate Management Team and Head of Program and Alliance Management. During her tenure, she supported the company's acquisition by Roche and oversaw key relationships with partners including Pfizer and Novartis.

Lauren began her career at GlaxoSmithKline (GSK), where she held leadership roles in research, operations, and business development. As part of GSK’s Worldwide Business Development team, she managed a portfolio of more than 20 alliances with biotech, diagnostic, and venture partners.